Cantor Fitzgerald raised the firm’s price target on Legend Biotech (LEGN) to $75 from $66 and keeps an Overweight rating on the shares. Legend reported Q3 earnings, with sales for Carvykti reaching $524M in Q3, marking another record quarter for a CAR T-cell therapy, the analyst tells investors in a research note. The firm says the outlook for BCMA-directed CAR T therapy is robust, driven by earlier adoption, Carvykti’s overall survival benefit, and broader outpatient and community adoption.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech price target lowered to $90 from $94 at Barclays
- Legend Biotech’s Q3 2025: Strong CARVYKTI® Sales
- Legend Biotech’s Earnings Call Highlights Growth and Challenges
- Strong Buy Recommendation for Legend Biotech Driven by Market Position and Growth Potential
- Legend Biotech’s Strategic Growth and Risks: Analyst Assigns Hold Rating